New leukaemia treatment from Janssen approved

A new targeted anti-cancer therapy that helps improve survival in the most common form of leukaemia, Chronic Lymphocytic Leukaemia, has received regulatory approval in Australia. The treatment, from Janssen, is approved for Australians with CLL who have received at least one prior therapy or who have a chromosome anomaly known as 17p deletion. IMBRUVICA (ibruntinib)